Medical Condition News

RSS

Ancient berry could protect against diabetic retinopathy

The ancient Tibetan goji berry could help fight blindness caused by long-term diabetes according to studies conducted by University of Sydney researchers.

5 Jun 2012

Bloomberg's proposed super-size soda ban is latest attack on portion size in war against obesity

New York City mayor seeks to limit the size of sugary beverages but the plan draws scorn from the soft drink industry and heightens the debate about how involved government should be in efforts to "steer individual behavior in the name of health."

5 Jun 2012

HDL to offer testing services based on Critical Diagnostics' Presage ST2 Assay

Critical Diagnostics, a U.S.-based biomarker company focused on cardiovascular diseases and Health Diagnostic Laboratory, Inc. (HDL, Inc.), announced today an agreement under which HDL, Inc. will soon offer ST2 testing services based on Critical Diagnostics' Presage ST2 Assay.

5 Jun 2012

Cannabinoid therapy helps provide effective analgesia for cancer patients with pain

An investigational cannabinoid therapy helped provide effective analgesia when used as an adjuvant medication for cancer patients with pain that responded poorly to opioids, according to results of a multicenter trial reported in The Journal of Pain, published by the American Pain Society.

5 Jun 2012

New data from CardioFocus’ HeartLight EAS clinical study on AF

CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announces new worldwide data with its technology was presented during the scientific sessions at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions, in Boston, MA last month.

5 Jun 2012

Scientists discover neural mechanism for conscious perception

When people close their eyes, they can form mental images of things that exist only in their minds. Neuroscientists studying this phenomenon at medical schools in the Texas Medical Center believe that there may be a way to use these mental images to help some of the estimated 39 million people worldwide who are blind.

5 Jun 2012

Jennerex announces data from JX-594 clinical studies on cancer

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that data relating to the company's oncolytic virus therapy for cancer was featured in three separate abstracts during the American Society of Clinical Oncology (ASCO) Annual Meeting currently taking place in Chicago, Illinois.

5 Jun 2012

Esperance presents results from EP-100 Phase 1 study on solid tumors at ASCO annual meeting

Esperance Pharmaceuticals presented its Phase 1 study of EP-100, a novel targeted membrane‐disrupting peptide (tMDP) in advanced solid tumors at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

5 Jun 2012

Researchers identify predictive biomarker for Parkinson's disease

Because there is currently no laboratory test that can diagnose Parkinson's disease, it is practically impossible to detect those individuals who are in the earliest stages of the disease. As a result, Parkinson's disease can only be diagnosed by a clinical neurological examination based on findings suggestive of the disease.

5 Jun 2012

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation today announced results from a study of ABRAXANE(paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in patients with resectable pancreatic cancer.

5 Jun 2012

HCMS, ACOEM announce important expansion to Blueprint for Health

The American College of Occupational and Environmental Medicine (ACOEM) and the HCMS Group have announced an important expansion to their "Blueprint for Health" - a free internet-based calculating tool that helps employers better comprehend and analyze the impact of medical costs, absence, and work impairment among their employees.

5 Jun 2012

Alnylam announces results from ALN-VSP Phase I study on liver cancers

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced results today from its Phase I extension study with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

5 Jun 2012

High doses of ginseng more effectively reduce cancer-related fatigue in patients

High doses of the herb American ginseng (Panax quinquefolius) over two months reduced cancer-related fatigue in patients more effectively than a placebo, a Mayo Clinic-led study found. Sixty percent of patients studied had breast cancer. The findings are being presented at the American Society of Clinical Oncology's annual meeting.

5 Jun 2012

ASS234 molecule inhibits aggregation of the Alzheimer's protein

Researchers at Universitat Aut-noma de Barcelona (UAB), the Spanish National Research Council (CSIC) and the University of Barcelona (UB) have developed a multitarget molecule, ASS234, which according to the results of in vitro studies conducted, inhibits the aggregation of the --amyloid protein, involved in Alzheimer's disease.

5 Jun 2012

Senesco reports on the progress of SNS01-T Phase 1b/2a study for multiple myeloma

Senesco Technologies, Inc. reported today on the progress of its Phase 1b/2a study for the treatment of multiple myeloma, which is the subject of a poster presented today at the 2012 Annual Meeting of the American Society of Clinical Oncology.

5 Jun 2012

Researchers uncover brain signaling pathway responsible for renal excretory function

Boston University School of Medicine (BUSM) researchers recently uncovered a brain signaling pathway responsible for regulating the renal excretion of sodium. The findings appear in the Journal of the Federation of American Societies for Experimental Biology.

5 Jun 2012

Exelixis reports data from cabozantinib phase 3 trial on MTC

Exelixis, Inc. today reported data from the phase 3 pivotal trial of cabozantinib in patients with progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC).

5 Jun 2012

Promising data from Array BioPharma’s MEK162 Phase 2 trial on BRAF and NRAS mutant melanoma

Promising data on MEK162 in an ongoing Phase 2 trial of patients with BRAF and NRAS mutated advanced melanoma was presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

5 Jun 2012

OncoGenex announces data from OGX-427 Phase 2 study on mCRPC

OncoGenex Pharmaceuticals, Inc. announced today data from a Phase 2 study of its investigational compound OGX-427 in chemotherapy-naive metastatic castration resistant prostate cancer (mCRPC) patients will be presented during an oral presentation at the 2012 American Society of Clinical Oncology (ASCO) annual meeting on Tuesday, June 5.

5 Jun 2012

Chatham, Baxter partner to develop and commercialize hemophilia B gene therapy treatment

Baxter International Inc. today announced that it has entered into an exclusive global agreement with Chatham Therapeutics, LLC, an affiliate of Asklepios BioPharmaceutical, Inc. (AskBio), for the development and commercialization of potential treatments for hemophilia B utilizing Chatham's gene therapy technology.

From Baxter International Inc. 5 Jun 2012

Medical Condition News

Ancient berry could protect against diabetic retinopathy

Bloomberg's proposed super-size soda ban is latest attack on portion size in war against obesity

HDL to offer testing services based on Critical Diagnostics' Presage ST2 Assay

Cannabinoid therapy helps provide effective analgesia for cancer patients with pain

New data from CardioFocus’ HeartLight EAS clinical study on AF

Scientists discover neural mechanism for conscious perception

Jennerex announces data from JX-594 clinical studies on cancer

Esperance presents results from EP-100 Phase 1 study on solid tumors at ASCO annual meeting

Researchers identify predictive biomarker for Parkinson's disease

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

HCMS, ACOEM announce important expansion to Blueprint for Health

Alnylam announces results from ALN-VSP Phase I study on liver cancers

High doses of ginseng more effectively reduce cancer-related fatigue in patients

ASS234 molecule inhibits aggregation of the Alzheimer's protein

Senesco reports on the progress of SNS01-T Phase 1b/2a study for multiple myeloma

Researchers uncover brain signaling pathway responsible for renal excretory function

Exelixis reports data from cabozantinib phase 3 trial on MTC

Promising data from Array BioPharma’s MEK162 Phase 2 trial on BRAF and NRAS mutant melanoma

OncoGenex announces data from OGX-427 Phase 2 study on mCRPC

Chatham, Baxter partner to develop and commercialize hemophilia B gene therapy treatment

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Latest News